NCT05191771

Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction

Multicentric, Randomized, Comparative Clinical Study on the Evaluation of the Efficacy and Safety of Neovis® Total Multi Versus Systane® Balance on the Treatment of Ocular Dryness Associated With Meibomian Gland Dysfunction

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Horus Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicentric, comparative, randomized, investigator-blinded, in parallel groups study to demonstrate the non-inferiority of Neovis® Total Multi in comparison with Systane® Balance, in terms of improvement of stability of Tear film in patients with eye dryness associated to meibomian gland dysfunction, after 28 days of treatment.

Conditions

• Dry Eye
• Meibomian Gland Dysfunction

Interventions

Type	Name	Description
DEVICE	Neovis Total Multi	1 drop in each eye, 4 times per day
DEVICE	Systane Balance	1 drop in each eye, 4 times per day

Timeline

• Start date: 2022-01-01
• Primary completion: 2022-10-01
• Completion: 2022-12-01
• First posted: 2022-01-13
• Last updated: 2022-01-13